retrosternal mass: an interesting allergic reaction to intravenous thrombolytic therapy for acute ischemic stroke.
Authors
abstract
stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage. however, other adverse reactions, including anaphylaxis and angioedema, can also occur. here we report an interesting soft tissue reaction to intravenous r-tpa in an 80 year-old male who was treated for acute ischemic stroke.
similar resources
Retrosternal mass: An interesting allergic reaction to intravenous thrombolytic therapy for acute ischemic stroke
Stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. Thrombolysis with recombinant tissue plasminogen activator (r-TPA) is the approved treatment for acute ischemic stroke. A major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-TPA,) is the risk of intracerebral hemorrhage...
full textIntravenous thrombolytic therapy for acute ischemic stroke.
n engl j med 364;22 nejm.org june 2, 2011 2138 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...
full textIntravenous Thrombolytic Therapy for Acute Ischemic Stroke
n engl j med 364;22 nejm.org june 2, 2011 2138 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...
full textSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...
full texteligibility assessment for intravenous thrombolytic therapy in acute ischemic stroke patients; evaluating barriers for implementation
conclusions: the major barriers for thrombolytic therapy for patients with ais in this setting were delays in the provision of in-hospital services, like initial patient assessment, ct scans or laboratory studies. these results were in contrast with previous reports. background: intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (ais) and is recomme...
full textEligibility Assessment for Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients; Evaluating Barriers for Implementation
BACKGROUND Intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (AIS) and is recommended by multiple guidelines. However, it seems that it is less frequently used in the developing countries compared to the developed countries. OBJECTIVES The purpose of this study was to estimate the percentage of patients with AIS, eligible for intravenous thrombol...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of neurologyجلد ۱۲، شماره ۳، صفحات ۱۱۴-۱۱۶
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023